<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> WSJ881026-0024 </DOCNO><HL> Who's News: Amgen Selects Binder As Chief Executive, Hixson as President </HL><SO> </SO><CO> WNEWS AMGN </CO><DATELINE> THOUSAND OAKS, Calif.  </DATELINE><TEXT>   Amgen Inc. named two of its executives to succeed the company's longtime chief executive officer and president, George B. Rathmann, who continues as chairman of the board and of the executive committee.    Gordon M. Binder, 53 years old, was elected chief executive. Harry F. Hixson Jr., 50, was elected president and chief operating officer, a new post. Both men were named directors, increasing the size of the board to 10.    Mr. Rathmann, 60, said he proposed the changes as part of a natural transition from a research company to an operating company. Amgen, a biotechnology concern, is awaiting Food and Drug Administration approval to market its first genetically engineered drug.    Mr. Binder had been senior vice president and chief financial officer, and Mr. Hixson had been senior vice president, business operations.    Daniel Vapnek, 49, former vice president-research, was elected senior vice president-research. Lowell Sears, 37, former treasurer, was elected vice president-finance, and chief financial officer. </TEXT></DOC>